UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Net income	$ 2,789	$ 1,336
Depreciation and amortization	820	265
Gain on investments		(6)
Provision for losses on accounts receivable	7	4
Deferred income taxes	(251)
Stock-based compensation expense	20	24
Accounts receivable - trade	(1,227)	323
Accrued interest and other receivables	(49)	(52)
Inventories	241	(203)
Prepaid expenses and other current assets	(70)	(105)
Accounts payable	309	345
Accrued expenses	882	383
Deferred revenue	(25)
Other liability		449
Total adjustments	657	1,427
Net cash provided by operating activities	3,446	2,764
Capital expenditures for property and equipment	(72)	(19)
Capital expenditures for intangible assets	(1)	(5)
Purchases of investments		(500)
Proceeds from sale of investments		15,155
Net cash paid in acquisition		(41,084)
Net cash provided by (used in) investing activities	(74)	(26,452)
Proceeds from issuance of common stock - options	585	36
Tax benefit attributable to exercise of stock options	55	10
Proceeds from notes payable		26,934
Repayment of notes payable	(2,464)	(132)
Net cash provided by (used in) financing activities	(1,824)	26,849
Effect of exchange rate changes on cash	76	30
NET INCREASE (DECREASE) IN CASH	1,624	3,190
CASH AT BEGINNING OF PERIOD	6,534	3,818
CASH AT END OF PERIOD	8,159	7,008
Cash paid during the period for interest	$ 189	$ 51